Coloplast (COLO) Investor presentation summary

Strategic priorities and business model

• Focus on four strategic priorities: innovative customer offerings, efficiency gains, technology adoption, and cultivating a winning, sustainable company.

• Business model centers on customer needs, with strong service offerings and innovation in Chronic and Acute Care segments.

• Five global business areas: Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology.

• Dynamic resource allocation shifts investment from low-performing to high-potential areas, especially in the US, Kerecis, and technology.

Financial performance and guidance

• Q3 2025/26 organic growth was 6%, with EBIT growth of 5% in constant currencies; EBIT margin at 26%.

• 9M 2025/26 organic growth was 6%, driven by Chronic Care and Interventional Urology; reported revenue up 3% due to currency headwinds.

• FY 2025/26 guidance unchanged: 5-6% organic growth, EBIT growth around 5% in constant currencies, ROIC around 15%.

• Free cash flow-to-sales ratio improved to 20% in 9M 2025/26, supported by positive working capital and lower net financial items.

Segment and geographic performance

• Ostomy Care ex. China delivered 7% organic growth, with double-digit growth in the US; China impacted by inventory reduction and weak sentiment.

• Continence Care grew 8%, led by Luja catheter and strong US/Europe performance.

• Voice & Respiratory Care up 6%, with Laryngectomy strong and Tracheostomy softer.

• Wound & Tissue Repair returned to 3% growth, but Biologics declined 6% due to US reimbursement changes.

• Interventional Urology grew 7%, driven by US Men's Health and new product launches.

• European markets contributed 57% of Q3 organic growth; other developed markets 43%.